Up next

Autoplay

The use of hydroxyurea for treating SCD in Sub-Saharan Africa

0 Views • 08/19/25
Share
Side Effects
Side Effects
Subscribers
0

Leon Tshilolo, MD, PhD, Centre Hospitalier Monkole, Kinshasa, DR Congo, discusses the use of hydroxyurea for the treatment of sickle cell disease (SCD) in sub-Saharan Africa (SSA), highlighting the main limitations to the widespread implementation of this agent. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Show more
0 Comments sort Sort By

Up next

Autoplay